Tongue Carcinoma

Bioinformatic analyses further indicated that the rs4274 A allele is associated with increased MIAT expression, and higher MIAT levels correlated with higher tumor grade. In conclusion, the MIAT rs4274 A allele is linked to poorer tumor differentiation, particularly among betel-quid chewers and smokers, and elevated MIAT expression supports its potential as a biomarker of tumor aggressiveness.

IL-17 inhibitor administration is associated with an elevated incidence of oral complications, particularly oral candidiasis and herpetic infections, highlighting the importance of clinician awareness and assessment of oral complications during IL-17 inhibitors therapy.

Currently, NIR-PIT is approved only in Japan for the treatment of unresectable, locally recurrent head and neck squamous cell carcinoma, using the anti-epidermal growth factor receptor antibody cetuximab and the photoabsorber IR700...After confirming the absence of tumor recurrence, the patient was successfully treated using a well-vascularized pedicled flap. This case highlights two key management considerations for NIR-PIT-induced skin injury: surgical indications and cancer treatment. Further studies are necessary to improve the management of severe skin complications following NIR-PIT.

Importantly, these potent anticancer effects were conserved in another OSCC cell line (YD‑10B) and, were validated in vivo, where PP1 suppressed tumor growth in a zebrafish xenograft model. Collectively, these findings suggest that PP1 exerts strong anticancer effects on human oral cancer by simultaneously inhibiting Src activity and disrupting a network of associated oncogenic pathways (EGFR, STAT‑3, PKB and ERK‑1/2).

Overall, the effect of rs75267932 on TSCC progression was most pronounced in individuals exposed to lifestyle-related risk factors. These findings unveil gene-environment interactions in TSCC and highlight MIR17HG polymorphisms as potential biomarkers for risk assessment and disease monitoring in Asian men.

P2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2026 --> Jul 2025

Evidence for molecular and treatment-related factors is limited and requires further validation. These findings highlight the need for standardized reporting and prospective studies tailored to young-onset disease.

P=N/A, N=30, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

These findings indicate that CCNA2 is a promising diagnostic and prognostic biomarker candidate in OTSCC. Given the small size of the CPTAC validation cohort, further studies in larger, independent OTSCC cohorts are warranted to confirm its clinical utility.

The tumor progressed after two cycles of first-line induction chemotherapy with paclitaxel plus cisplatin. The response to disitamab vedotin, despite prior taxane progression, suggests the potential critical role of HER2-mediated drug delivery and indicates that low antigen density may be sufficient for ADC efficacy. This case indicates the importance of routine HER2 testing with explicit HER2-low categorization in advanced SGCs and offers preliminary evidence that may help expand therapeutic options for this treatment-refractory population.